Citius Pharmaceuticals
CTXR
5 hedge funds and large institutions have $112K invested in Citius Pharmaceuticals in 2017 Q3 according to their latest regulatory filings, with 5 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
0.02% more ownership
Funds ownership: 0% → 0.02% (+0.02%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$62.3K |
| 2 |
Goldman Sachs
New York
|
+$36.1K |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$5.93K |
| 4 |
CP
Corbenic Partners
Bethlehem,
Pennsylvania
|
+$5.61K |
| 5 |
Morgan Stanley
New York
|
+$624 |
Top Sellers
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Millennium Management
New York
| $63K | +$62.3K | +799 | New |
|
|
2
Goldman Sachs
New York
| $36K | +$36.1K | +463 | New |
|
|
CP
3
Corbenic Partners
Bethlehem,
Pennsylvania
| $6K | +$5.61K | +72 | New |
|
|
4
UBS Group
Zurich,
Switzerland
| $6K | +$5.93K | +76 | New |
|
|
5
Morgan Stanley
New York
| $1K | +$624 | +8 | New |
|
CTXR Hedge Fund Activity: Q3 2017 in Review
5 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Citius Pharmaceuticals (CTXR) for Q3 2017, worth a combined $112K.
Buyers outnumbered sellers: 5 funds opened new CTXR positions and 0 closed out — a net gain of 5 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Millennium Management, opening a new position worth an estimated $62.3K.
- 5 institutional investors held Citius Pharmaceuticals (CTXR) as of Q3 2017, up from 0 in Q2 2017.
- Funds reported $112K of Citius Pharmaceuticals stock for Q3 2017.
- 5 funds opened new Citius Pharmaceuticals positions in Q3 2017 and 0 closed out, a net change of +5 holders.
- The largest Citius Pharmaceuticals buyer in Q3 2017 was Millennium Management, an estimated $62.3K added.
Based on aggregated 13F filings for Q3 2017.